Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study

• Published in: PloS one Vol. 19; no. 3; p. e0299510
• Main Authors: Maeda, Makiko, Humber, Douglas, Hida, Eisuke, Ohtani, Tomohito, Wang, Guannan, Wu, Tong, Takeda, Shiori, Situ, Jacinta N, Hayashi, Jun, Nonen, Shinpei, Takeda, Toshihiro, Okamoto, Hiroshi, Hori, Masatsugu, Sakata, Yasushi, Fujio, Yasushi, Tsunoda, Shirley M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.03.2024; Public Library of Science (PLoS)
• Subjects: Adrenergic beta-Antagonists; Biology and Life Sciences; Carbazoles - therapeutic use; Cardiac patients; Care and treatment; Carvedilol - therapeutic use; Diagnosis; Heart beat; Heart Failure; Humans; Japan; Medical records; Medical research; Medicine and Health Sciences; Medicine, Experimental; People and Places; Propanolamines - therapeutic use; Research and Analysis Methods; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left - chemically induced; Japan; Southeast Asia
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0299510

The Japanese national guidelines recommend significantly lower doses of carvedilol for heart failure with reduced ejection fraction (HFrEF) management than the US guidelines. Using real-world data, we determined whether initial and target doses of carvedilol in Japanese patients (JPNs) differ from those in US patients (USPs), especially in Asian Americans (ASA) and Caucasians (CA), and investigated differences in outcomes. We collected data from the electronic medical records, including demographics, carvedilol dosing, tolerability, cardiac functional indicators like EF, cardiovascular events including all-cause deaths, and laboratory values from the University of California, San Diego Health and Osaka University. JPNs had significantly lower doses (mg/day) of carvedilol initiation (66 USPs composed of 38 CAs and 28 ASAs, 17.1±16.2; 93 JPNs, 4.3±4.2, p<0.001) and one year after initiation (33.0±21.8; 11.2±6.5, p<0.001), and a significantly lower relative rate (RR) of dose discontinuation and reduction than USPs (RR: 0.406, 95% confidence interval (CI): 0.181-0.911, p<0.05). CAs showed the highest reduction rate (0.184), and ASAs had the highest discontinuation rate (0.107). A slight mean difference with narrow 95% CI ranges straddling zero was observed between the two regions in the change from the baseline of each cardiac functional indicator (LVEF, -0.68 [-5.49-4.12]; LVDd, -0.55 [-3.24-2.15]; LVDd index, -0.25 [-1.92-1.43]; LVDs, -0.03 [-3.84-3.90]; LVDs index, -0.04 [-2.38-2.30]; heart rate, 1.62 [-3.07-6.32]). The event-free survival showed no difference (p = 0.172) among the races. Conclusively, despite JPNs exhibiting markedly lower carvedilol doses, their dose effectiveness has the potential to be non-inferior to that in USPs. Dose de-escalation, not discontinuation, could be an option in some Asian and ASA HFrEF patients intolerable to high doses of carvedilol.